Although BRAF testing was not included in the previous Japan Lung Cancer Society guidelines, it was added in 2018, given that dabrafenib in combination with trametinib has now been established as a standard of care option for NSCLC patients with BRAF mutation [9,10]. Here, BRAF is linked to lung carcinoma.